Results 291 to 300 of about 112,622 (301)
Some of the next articles are maybe not open access.
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
Nature Reviews Clinical Oncology, 2018Alan Ashworth, Christopher J Lord
exaly
An update on PARP inhibitors—moving to the adjuvant setting
Nature Reviews Clinical Oncology, 2014Amir Sonnenblick +2 more
exaly
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
Nature Reviews Molecular Cell Biology, 2017Arnab Ray Chaudhuri
exaly
Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer
Nature Reviews Clinical Oncology, 2016Angela George, Susana Banerjee
exaly
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Nature Reviews Cancer, 2019Jonathan J Havel +2 more
exaly
The evolving landscape of tissue‐agnostic therapies in precision oncology
Ca-A Cancer Journal for CliniciansVivek Subbiah +2 more
exaly

